• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23589 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2027     Norwegian Medical Products Agency (NOMA) [Wearable cardioverter defibrillator for people with high risk of sudden cardiac arrest: a single technology assessment]
2027     Belgian Health Care Knowledge Centre (KCE) Review of new oncology indications for the use of positron emission tomography (PET-scans) (Study 2024-12)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2025     NIHR Health and Social Care Delivery Program Systematic review of integrated mental and physical health services for children and young people with eating and functional symptoms
2025     Belgian Health Care Knowledge Centre (KCE) Cost-effectiveness of maternal immunisation by Abrysvo® or a single injection of a monoclonal antibody (Beyfortus®) in infants for infant protection against infection by the respiratory syncytial virus in Belgium (Study 2024-51)
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “type 2 diabetes”]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Phonocardiography to rule out coronary heart disease]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a decision aid for carotid revascularization surgery for carotid stenosis]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Pharmacological treatment of polycystic ovary syndrome - health and quality of life in the short and long term]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions for behavioural change in the aim of promoting health and preventing disability in the elderly]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Psychometric properties for instruments used to measure core outcomes for provoked vestibulodynia]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Accuracy of diagnostic algorithms for suspected or elevated risk of ovarian cancer]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Newborn screening for Metachromatic leukodystrophy (MLD)]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions to formal caregivers for increased patient safety]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Digital technology promoting health for children and adolescents]
2025     The Danish Health Technology Council (DHTC) [Assessment of treatment of knee pain]
2025     The Danish Health Technology Council (DHTC) [Assessment of forearm fractures in children]
2025     The Danish Health Technology Council (DHTC) [Assessment of point-of-care tests for use at home for elderly patients]
2025     The Danish Health Technology Council (DHTC) [Assessment of HAL-assisted TUR-BT]
2025     The Danish Health Technology Council (DHTC) [Assessment of SelfBack App for lower back pain]
2025     The Danish Health Technology Council (DHTC) [Assessment of supervised gait training]
2025     The Danish Health Technology Council (DHTC) [Assessment of Merlin Assay for diagnosis of malignant melanoma]
2025     The Danish Health Technology Council (DHTC) [Assessment of percutaneous vertebroplasty (PVP) for compression fractures]
2025     The Danish Health Technology Council (DHTC) [Assessment of endovascular aortic repair (EVAR)]
2025     Swiss Federal Office of Public Health (FOPH) Betahistine or cinnarizine with or without dimenhydrinate for Ménière’s disease/syndrome and symptoms of vestibular vertigo and/or tinnitus
2025     Norwegian Medical Products Agency (NOMA) [Continuous and flash glucose monitoring in patients with type 2 diabetes treated with insulin]
2025     Norwegian Medical Products Agency (NOMA) [Photon-counting detector computed tomography]
2025     Norwegian Medical Products Agency (NOMA) [Volatile gas capture technology. Summary of a health technology assessment by Scottish Health Technologies Group: health technology assessment without submitted documentation]
2025     Norwegian Medical Products Agency (NOMA) [Tumor-treating fields (Optune) for treatment of glioblastoma: a rapid health technology assessment with submitted documentation]
2025     Norwegian Medical Products Agency (NOMA) [Magnetic resonance guided high-intensity focused ultrasound for treatment of essential tremor: single technology assessment]
2025     Norwegian Medical Products Agency (NOMA) [A leadless pacemaker, MicraTM Transcatheter Pacing System, in (sub-groups of) patients with indication for single-chamber ventricular pacing: a single technology re-assessment]
2025     Health Information and Quality Authority (HIQA) Health technology assessment (HTA) of teledermatology for triage of primary care referrals
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the tiered system of emergency structures in hospitals]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for prostate cancer]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [SSRI / SSNRI: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tricyclic antidepressants: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Agility training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anticonvulsants: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Strength training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endurance training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy for insomnia: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mindfulness-based stress reduction: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on lung cancer screening using low-dose computed tomography]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on smoking cessation options]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for implantation of unicondylar sled prosthesis - Update of Project V21-02]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome in knee replacement revision surgery - Update of Project V21-03]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for total knee replacement – Update of Project V21-01]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Scientific evaluation of the relationship between volume of services and quality of treatment outcome for rare diseases]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of cardiac magnetic resonance imaging in coronary heart disease]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radiofrequency energy treatment for organic erectile dysfunction]
2025     Norwegian Medical Products Agency (NOMA) Intravenous ketamine for treatment-resistant depression
2025     Belgian Health Care Knowledge Centre (KCE) Economic evaluation of whole genome sequencing for children with developmental disorders (Study 2024-09)
2025     Belgian Health Care Knowledge Centre (KCE) Update of prostate cancer screening recommendations (Study 2024-10)
2025     Belgian Health Care Knowledge Centre (KCE) Update of breast cancer screening recommendations (Study 2024-11)
2025     Belgian Health Care Knowledge Centre (KCE) Evaluation of novel blood-based brain biomarkers for mild traumatic brain injuries (Study 2023-11)
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection of graft damage in kidney and heart recipient patients using donor-derived free DNA (dd-cfDNA)]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Branched endovascular prostheses for the treatment of aortic arch pathology]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and clinical effectiveness of cryoanalgesia in pediatric patients after surgical intervention for pectus excavatum]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of care models based on the incorporation of psychologists in primary care]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of ex vivo confocal microscopy during Mohs surgery for basal cell carcinomas]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline (CPG) update palliative care]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline on deprescribing antidepressants]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Adaptive deep brain stimulation in Parkinson's disease]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [SSRI/SSNRI: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cimicifuga: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for major liver resection]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irradiation of the skin with intense pulsed light and radiofrequency for stage I and II hidradenitis suppurativa (Hurley Score)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Adhesions in the abdominal cavity: Do other measures help to relieve symptoms instead of surgery?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2025     Swiss Federal Office of Public Health (FOPH) Multigene-expression tests for breast cancer
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effectiveness and complications of preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Alternative methods to coercive measures]
2025     NIHR Health Technology Assessment programme Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: confirmed chlamydia trachomatis or neisseria gonorrhoeae infection]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of STAT5 phosphorylation status by flow cytometry]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of STAT3 phosphorylation status by flow cytometry]
2024     Health Information and Quality Authority (HIQA) A summary of publicly-funded services for fertility preservation for medical reasons in selected countries
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Benefits and risks of emergency departments with or without a co-located primary care driven urgent care center
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Umbilical cord clamping at one minute, allowing stem cell harvesting, compared with delayed cord clamping - infant and maternal outcomes
2024     Haute Autorite de sante (HAS) [Assessment of the endoscopic transluminal necrosectomy procedure in the treatment of acute necrotizing pancreatitis]
2024     Norwegian Institute of Public Health (NIPH) [Cost-effectiveness of robot assisted surgery for prostate cancer]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Stereotactic radiosurgery in benign tumors of the central nervous system]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: syndromic approach - pharmacological treatment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: genital herpes - identification, diagnosis, optimal use of antivirals and follow-up]
2024     National Institute for Health and Care Excellence (NICE) Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome. NICE diagnostics guidance 62
2024     National Institute for Health and Care Excellence (NICE) Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant. NICE interventional procedures guidance 795
2024     National Institute for Health and Care Excellence (NICE) MRI-guided focused ultrasound subthalamotomy for treating Parkinson's. NICE interventional procedures guidance 797
2024     National Institute for Health and Care Excellence (NICE) MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's. NICE interventional procedures guidance 796
2024     National Institute for Health and Care Excellence (NICE) Bevacizumab gamma for treating wet age-related macular degeneration. NICE technology appraisal guidance 1022
2024     National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1021
2024     National Institute for Health and Care Excellence (NICE) Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal). NICE technology appraisal guidance 1024
2024     National Institute for Health and Care Excellence (NICE) Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1023
2024     National Institute for Health and Care Excellence (NICE) Ublituximab for treating relapsing multiple sclerosis. NICE technology appraisal guidance 1025
2024     National Institute for Health and Care Excellence (NICE) Tirzepatide for managing overweight and obesity. NICE technology appraisal guidance 1026
2024     HTA Region Stockholm [Effectiveness and safety of intense pulsed light therapy for dry eye symptoms due to meibomian gland dysfunction]